BD (NYSE:BDX) announced today that it named Michelle Quinn as acting general counsel for the company.
Quinn succeeds Samrat (Sam) Khichi in the role. Khichi informed the company of his intent to depart for a new opportunity, effective Feb. 3, 2023.
Reporting to chair, president and CEO Tom Polen, Quinn holds responsibility for leading the law group at BD. She is also set to become a member of the company’s executive leadership team.
Quinn joined BD in 2019. She currently serves as SVP, deputy general counsel and chief ethics and compliance officer. Prior to that, she served as VP and general counsel of North America for Sandoz, a division of Novartis. Before that, she held the role of VP and associate general counsel at Catalent Pharma Solutions.
“Michelle brings more than two decades as a corporate leader and strategic business advisor, and in the four years since joining BD she has significantly elevated our legal, ethics and compliance practices,” Polen said. “I’m confident that under her leadership, she will help us advance our BD 2025 strategy as we continue to operate as the more agile and innovative MedTech leader we are today.
“I also want to thank Sam for his significant contributions and his instrumental role in helping shape BD 2025, setting us on the path that is transforming the future of BD. He has made an enormous mark at the company developing and leading teams that have been paramount in driving business-critical work, helping shift our portfolio into transformative spaces and advancing our culture for operating as a best-in-class organization.”
Further leadership changes at BD
As part of the leadership transition, EVP and Chief Regulatory Officer Ami Simunovich will report directly to Polen. BD’s Public Affairs arm will report to Simunovich.
BD also intends for its Corporate Development arm to report to Chris DelOrefice, EVP and CFO. The company said this brings a closer alignment between corporate development and corporate strategy.